The limitations of existing imaging techniques for kidney disease present a pressing clinical need. Ten percent, are living with chronic kidney disease (CKD). CKD can progress to end-stage kidney disease (ESKD) and increases cardiovascular risk [12]. This consumes considerable resources; CKD-associated costs in England are estimated at £1.45billion per annum [13]. Better imaging to determine pathophysiology and prognosis of kidney diseases would improve stratification of patients and allow better targeting of treatments.
Over-arching aim of the AFiRM Study, is to determine if multiparametric renal MRI can provide structural and functional assessment of the kidneys in people with CKD that will (1) provide prognostic information and (2) guide treatment options.